chrisvoncsefalvay/vaers-outcomes huggingface dataset:
>35 days since first dose,  My first dose was March 18. How long can I go between doses; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (>35 days since first dose,  My first dose was March 18. How long can I go between doses) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On 18-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (>35 days since first dose,  My first dose was March 18. How long can I go between doses). At the time of the report, PRODUCT DOSE OMISSION ISSUE (>35 days since first dose,  My first dose was March 18. How long can I go between doses) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       The concomitant medications were not reported.  The treatment information was not provided.
Sore arm muscle for over a week.  Couldn?t raise arm without pain.  Rest and heat helped.  The other issue was development of mouth ulcers about 4 days after vaccination.  Multiple mouth ulcers on bottom lip and gum (about 4-5) developed and spontaneously resolved within about 3 days.
Rash, itching, bumps along neck, and right eye (swollen eye, but decreased).
no adverse events; PROQUAD was administered after improperly stored; This spontaneous report as received from a medical assistant refers to a currently 4 year old patient of unknown gender. On 14-OCT-2021, the patient was vaccinated with an improperly stored dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) (lot # T027115 exp date 07-FEB-2022) (0.5 mL route not reported). The temperature of excursion was 6°F to 14°F (8.5 °F) for 18 minutes and 6°F to 14°F (11.9 F) for 1 hour. Cumulative timeframe was 1 hour and 18 minutes. There was no previous temperature excursion.
2-3 hours after vaccine administration pt developed crushing chest pain, nausea and metallic taste in mouth. Symptoms resolved after several minutes.
moderate injection site pain and swelling, fatigue after 1 day from vaccination, day 2 from vaccination developed unwell feeling and congestion, scratchy voice, and worsening fatigue
Numbness of tongue, change in taste, congestion, body aches, diarrhea, cough
In early February I had a little bit of clogged ears and congestion. As the day went on, I began to have a runny nose. On that day I tested negative for COVID-19. The next day I tested positive. I had more of a runny nose and fatigued with a slight fever. I contacted my doctor and was prescribed PAXLOVID. My energy level was better within four days. I had a metal taste from the PAXLOVID. I didn't have a fever Monday. I persisted with some congestion for about two weeks.
Freezer door was left open. Products are back under recommended storage range/confirmed that vaccines were administered after previous excursion; This spontaneous report has been received from a registered nurse concerning an unspecified number of patients of unknown age, gender and ethnicity. The patients concurrent conditions, known allergies/reactions, medical history and concomitant medications were not reported.   On an unspecified date, the patients were vaccinated with improperly stored doses of Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) (Lot # S022914 with expiration date 19-JAN-2021; Lot # T013541 with expiration date 17-OCT-2021; and lot # T009932 with expiration date 16-SEP-2021) and varicella virus vaccine live (Oka/Merck) (VARIVAX) (Lot # S024366 with expiration date 06-AUG-2021; Lot # T002846 with expiration date 23-JAN-2022; and lot # T010308 with expiration date 24-MAR-2022)  (dose, route of administration and anatomical location not provided) for prophylaxis. The reporter stated that a freezer door was left opened, and in consequence, the vaccines were exposed to a temperature excursion of -11.1 degree celsius (C) during a time frame of 1 hour and 4 minutes. The vaccines had previous temperature excursions (unspecified) reported. The excursion was called by a data logger.  This case in non-valid due to lack of patient identifiers.
Aching pain, swelling, warmth & erythema. Onset 2/25/12 - no relieving factors i e: cold compresses TYLENOL/ibup. Seen in office 3d after vaccine given Rx KEFLEX to cover cellulitis, induration marked with pen on 2/25/12 as instructed by on call nurse area 2/27/12 progressed - .5in.
Pt reported redness and warmth around injection site was reported 2 days after injection. Pt did not report any other symptoms.
pt recvd vax on 20NOV92 & on 29NOV92 was screaming & limp, felt warm, called ambulance & t103+;
Sleep apnea resolved, since the first vaccine; This is a spontaneous report received from a contactable reporter (Consumer) from medical information team.  A 23 year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) (Batch/Lot number: unknown) as dose 1, single for covid-19 immunization. Relevant medical history included: "Totally disabled" (ongoing); "Sleep Apnea" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: THERAPEUTIC RESPONSE UNEXPECTED (non-serious), outcome "unknown", described as "Sleep apnea resolved, since the first vaccine".  Additional information: Caller was 74. Caregiver for 23 year totally disabled. Both received vaccines at same time. Second dose was 19Mar2021. Sleep apnea resolved, since the first vaccine. Indicated that just has to lift chin and "immediately breathing".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
patient potentially received a vaccine  that was exposed to room temperature for over 26 hours after; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (patient potentially received a vaccine  that was exposed to room temperature for over 26 hours after) in a 19-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for an unknown indication.     Concurrent medical conditions included Penicillin allergy.    On 02-May-2022 at 6:15 AM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-May-2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced EXPIRED PRODUCT ADMINISTERED (patient potentially received a vaccine  that was exposed to room temperature for over 26 hours after). At the time of the report, EXPIRED PRODUCT ADMINISTERED (patient potentially received a vaccine  that was exposed to room temperature for over 26 hours after) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported. No treatment medication was reported.  Patient was not diagnosed for COVID-19. It was reported that vial that was left out of the fridge at 3pm on 1-May-2022 and used on 02-May-2022 at 6:15pm.
Got Vaccine Friday at noon.   Nauseous around 6pm, couldn't eat dinner, nauseous all night long, morning time chills, fever, achy, extremely weak.  Symptoms lasted badly until Monday morning and still felt weak on Tuesday.    Had period at time of vaccine.  Unusually heavy for first two days then lingered for 10 days, usually over at day 6.
Cerebral occlusion in middle cerebral artery; Developed SOB which lingered; This spontaneous case was reported by a health care professional (subsequently medically confirmed) and describes the occurrence of CEREBRAL ARTERY OCCLUSION (Cerebral occlusion in middle cerebral artery) in an 81-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Diabetes mellitus, Hypertension and Hyperlipidemia.    On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Feb-2021, the patient experienced DYSPNOEA (Developed SOB which lingered). On 03-Mar-2021, the patient experienced CEREBRAL ARTERY OCCLUSION (Cerebral occlusion in middle cerebral artery) (seriousness criterion hospitalization). The patient was hospitalized from 03-Mar-2021 to 06-Mar-2021 due to CEREBRAL ARTERY OCCLUSION. At the time of the report, CEREBRAL ARTERY OCCLUSION (Cerebral occlusion in middle cerebral artery) and DYSPNOEA (Developed SOB which lingered) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded. However, Patient's advanced age, hypertension, diabetes Miletus, hyperlipidemia may remain as risk factors for this event. Further information is requested.
About 15 minutes after pateint received the vaccine he began to feel a pressure in the area of the sterum and medial pectoral muscles, worse when he took a deep breath. He had no SOB< left sided chest pain, pain radiating to left arm or next, sweating, or dizziness. On exam HR 92 and regular, 2+ radial pulse b/l with brisk cap refill, heart normal S1, S2, no m/g/r, lungs CTA B with good aeration throughout, no wheezing, normal resp effort. +tenderness to palpation of the chest wall and along b/l edge of the sterum. Patient was observed for about 30 minutes. Symptoms still present but no progression and no new symptoms. He felt he could go back to work. Instructed him and supervisor that he should not do any streunuous activity. Shoudl he experience any worsening symptoms, any new symptoms such as chest pain or SOB then he should be evaluated right away. He may take ibuprofen or acetaminophen in needed for the chest wall discomfort.
Had her second  Gardasil vaccination at the end of August 2007, two weeks later suddenly developed pain in joints of hands, feet, knees and elbows. Pain got progressively worse and required emergency room visit when she could not bend her joints and was in extreme pain. Had multiple tests done and was given prednisone for the inflammation, pain medication and a referral to a Rhematologist. After 2 months of treatment with steroids and multiple blood tests for Lyme disease, Hepatitis and Lupus and others she was diagnosed with Rhematoid Arthritis. It came on out of the blue. She had never had any illness or symptoms prior to the sudden and unexplained onset. We went to the Clinic for a second opinion and they confirmed RA.  She has been on Methetrexate and Enbrel which she will have to stay on for the rest of her life. She still has stiffness, pain and inflammation even with the drugs. This happened just after her second dose of Gardisal. I believe there is a connection, prior to that she was a strong  healthy young woman with no history of any illness and never had joint pain. There is no history of autoimmune disease in either side of her family and it is extremely rare for RA to develop so suddenly and severely as it did in her case.  09/12/2008 MR received for ER visit 9/23/2007 with DX: arthralgias.  Pt presented with c/o 1 week hx of joint pain, now worsening in legs, wrists and shoulder as well as low grade fevers and polymyalgia.  Recently started on steroid taper by PCP however pain is now worse with lower extremity joint swelling. D/C on pain meds to f/u with rheumatologist.  Rheumatology consult dated 9/28/07 with impression Inflammatory Arthritis in multiple joints. HPI as above now with morning stiffness > 1 hr, fatigue, night sweats, cold sensitivity, nausea and paresthesias in the hands and feet. PE (+) for limping gait, polysynovitis, shoulder, elbow and wrist tenderness with decreased ROM, PIP joints swollen and tender, effusions in both knees, ankles and forefeet tender. Started on prednisone. 11/24/08 Additional records received fron another Rheumatologist beginning 2/6/08 for sudden onset symmetric polyarthritis in 9/2007.  Pt reports awoke one morning and could not move. Sx as above with addition of difficulty falling asleep. PE (+) for dry skin with MP rash on extremities and some periorbital swelling/erythema, joint swelling with decreased ROM. DX: Sero(+) RA, non-erosive. F/u 5/28/2008 reports increased pain and swelling and decreased appetite. Pt tearful re: loss of social life. 1/27/2010 Patient continues to suffer from an autoimmune disease we believe was a result of this vaccine
Patient arm swelled up and was not painful but stiff. It itched constantly and lasted for about 3-4 weeks. Onset occurred within a day or two.
Pt presents to the ED for c/o L anterior chest wall pain after receiving covid19 vaccination today around 1030. Pt reports she received the first dose in the L bicep. Pt reports after she received that shot she started having L anterior chest wall pain. Pt states she doesn't have any chest tightness but does have stabbing pain to the L anterior chest wall. Pt denies any difficulty breathing or hives or any allergic reaction. Pt was hooked up to cardiac/sp02 and BP monitoring equipment. Medication: Ibuprofen Route: PO Dose:800 mg Patient tolerated medication well; no adverse reaction noted. Medication: Tylenol Route: PO Dose:975 mg Patient tolerated medication well; no adverse reaction noted.
As reported by mother, at 11 AM child screamed with abdominal and stomach pain. Mother called Drs. office and talked with nurse who said the symptoms should go away and if they didn't bring child in. Pain subsided in 30 minutes. No more complaints until 11/25/09 and child reported stomach pain again and at this time had difficulty swallowing solid food. Could drink liquids without difficulty. On 11/26/09 through 11/28/09 child demonstrated no symptoms other than when asked the child would state his stomach hurt. On 11/29/09 child would not eat. Mom called Drs. office and talked to the nurse, relating symptoms and telling nurse childs lips were purplish. Nurse said to take child to the ER. Blood and urine tests, as well as X-Rays done at ER. Mother states Dr. said he couldn't find anything wrong and child should not be having these symptoms. Sent home from ER. On 11/30/09 mother called Drs. office and nurse said to bring child in. Dr. ran some more tests which came out normal. Mother states Dr. called the drug (H1N1) company and was told they had not had any such symptoms reported. Dr. talked with another Dr. in office and decided it was an allergic reaction to the H1N1 vaccination received on 11/20/09. Prednisolone 15 mg. per ml. take 7.5 ml. per day po prescribed for child. On 12/01/09 mother states child still cannot eat but not screaming with stomach pain. 12/10/11/21/2009 ED records for 11/29/2009, c/o's abdominal pain, lack of appetite, dysphagia, cyanotic around mouth and lips 12/10/2009 ENT consult records for 12/10/2009
Patient reported history as noted above. She relayed a coincident IVF cycle pregnancy loss. Further clinical details unknown by this facility. Submitted for consideration of possible association and further discussion with treating providers.
Information and follow-up information has bee received from a physician concerning a 17 year old Asian female patient who on 02-APR-2008 approximately at 6:00pm, was vaccinated intramuscularly in the arm with a first dose of GARDASIL. The patient fainted right after getting the first dose of GARDASIL walking out from a room. The patient recovered quickly at 6:25 pm. No further information is available.
Pain, loss of motion in arm, shoulder, seems to be getting worse. Ibuprofen helps to control it.
Information has been received from a registered pharmacist reporting on a patient of unknown age and gender. There was no information about the patient's concurrent conditions, medical history, concomitant medication or drug reactions/allergies. On 09-SEP-2017, the patient was vaccinated with ZOSTAVAX 19400 PFU lot # M035694, expiry date 07-NOV-2017, reconstituted with sterile diluent (MRK) lot # M020945, expiry date 05-DEC-2018 for prophylaxis (dose, route of administration were not reported). During the administration there was a leak from the syringe where some of the reconstituted vaccine dripped on the patient's arm and patient did not receive a full dose of ZOSTAVAX (underdose). The pharmacist stated that the syringe may not have been fully secured. No adverse effects being reported.
pt devel gen hives 21hrs p/vax;pt went to ER 830PM on 19JUL96 & given Epi & started on DPH & pred;
Initial and follow up information has been received from a nurse, for the pregnancy for GARDASIL, concerning a black female with one previous pregnancy and one full term delivery with no birth defects who was vaccinated with a 1st dose of GARDASIL when she was 5 weeks pregnant (previously reported as 16 weeks gestation on 11-Jun-2008) with LMP of 04-Mar-2008 (previously reported as approximately 15-Feb-2008). Other therapies included prenatal vitamins (unspecified). No adverse events reported. On 14-May-2008 the patient had a routine ultrasound, results indicated that the dating was 9w6D and estimated delivery date was 11-Dec-2008. The patient outcome was not reported. Additional information has been requested. Follow up information has been received from a complete pregnancy questionnaire on 30-Dec-2008 for the pregnancy registry for GARDASIL, concerning a black female patient with one previous pregnancy, no pertinent medical history and no known allergies who on an unspecified date was vaccinated with a dose of GARDASIL when she was 5 weeks pregnant (LMP: 04-Mar-2008). On 14-May-2008 the patient had a routine ultrasound, results indicated the age of the fetus was 9 weeks and 6 days and on 19-Nov-2008 the patient delivered a normal infant. In the following up information received on 30-Dec-2008 contained the following adverse experiences: gestational diabetes mellitus which was treated with Metformin (500-750 mg daily). No further information is available.
Pt vaccinated with DTP/OPV/HIB expired 7 hrs later. Dx SIDS.
Moderna vaccine was administered outside of facility- reported by patient  PULMONARY EMBOLISM, UNSPECIFIED. 6/22/2021 CANCER METASTATIC TO BONE HYPOXEMIA 6/12/2021 CANCER METASTATIC TO BONE PULMONARY EMBOLISM, UNSPECIFIED. 6/22/2021 CANCER METASTATIC TO AXILLARY LN HYPOXEMIA 6/12/2021 CANCER METASTATIC TO AXILLARY LN
as I waited for the second vax I got it again; This case was reported by a consumer via interactive digital media and described the occurrence of shingles in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   The patient's past medical history included shingles.   On an unknown date, the patient received the 1st dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced shingles. On an unknown date, the outcome of the shingles was unknown.   It was unknown if the reporter considered the shingles to be related to Shingles vaccine.  Additional details were provided as follows: The case was reported by the consumer for herself/himself. The age at vaccination was not reported. The patient reported that, he/she got Shingles vaccine and as the patient waited for the second vaccine he/she got the shingles again.  The patient said, not fun, take care of yourself.
today rash that is itchy; been itching off and on for the past week; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (been itching off and on for the past week) and RASH (today rash that is itchy) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was reported.  Concomitant products included EPINEPHRINE (EPIPEN), HYDROXYCHLOROQUINE, SPIRONOLACTONE, SALBUTAMOL (ALBUTEROL HFA) and VITAMIN D3 for an unknown indication.    On 29-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Apr-2021, the patient experienced PRURITUS (been itching off and on for the past week). On 14-Apr-2021, the patient experienced RASH (today rash that is itchy). At the time of the report, PRURITUS (been itching off and on for the past week) and RASH (today rash that is itchy) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.        Other concomitant was Breo inhaler. No treatment information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 08-May-2021: NNI
Patient is a YO F who presents for OCD. Patient has been well managed on her medications for several months. She says that she got her COVID shot on saturday and since then her psychiatric health has taken a dramatic decline. She is crying in the interview, reporting extreme anxiety, and mood swings. She denies any medical problems from the shot, but feels that it has destroyed her mental health. States that in one moment she will be happy and then later in the night she starts snapping at her husband. Sometimes she gets bursts of energy and starts doing a lot and cleaning a lot. Patient says her thoughts are driving her crazy. She says, "what's the point of feeling bad all the time." States she has had several really bad dreams in the last several nights that felt very real. Patient says she feels nauseas. Feels like her body wants to crawl out of her body. She feels like she movement makes it better. Patient says everything scares her.   Patient has been stable for several months on this medication regimen. Despite significant life events in the last several months, including a miscarried grandchild, patient did well prior to her recent shot.
Significant eye pain, swelling, puffiness, blurry vision, and headache, disorientation. started 3 hours after receiving second dose of covid/pfizer vaccine and continues 2 days later. Has NOT resolved
Pt recvd Engerix-B & devel flu sx & became tired x 3 days; Reporter is not sure how many doses of Engerix-B recvd;
suspected vaccination failure; 15 people I have spoken to who said they experienced shingles / all of them say they got it after; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a adult patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.  Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but was captured as adult as per vaccine indication.  The patient received Shingles vaccine and experienced shingles. This case was considered as suspected vaccination failure since the details regarding completion of primary vaccination schedule, time to onset and laboratory test confirming shingles were unknown at the time of reporting. This case was 1 of the 16 cases reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR088476:
Information concerning an 11 year old male pt who was vaccinated with a dose of pneumococcal vaccine 14 polyvalent. The pt developed sepsis and subsequently died. The case of death was sepsis.